Anlon Healthcare (AHCL)

FairStock Score: 59/100 — STEADY

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarter profitable: sales ₹36 Cr and net profit ₹5 Cr
• Healthy ROCE of 24.83% with manageable debt/equity of 0.27
• Piotroski F-Score 7/9 indicates solid financial health
• Promoter holding of 52.68% aligns owner interest
• Massive sales and profit growth of 280% and 306% respectively

Concerns

• P/B of 28.13 with book value of only ₹5.11 implies a very thin equity base and high valuation
• Zero dividend yield means investors rely solely on price appreciation
• Growth of 280%/306% is from a low base and likely unsustainable at this pace
• Stock trades at its 52-week high of ₹143.75, leaving no margin of safety

AI Analysis

When I see a stock that has gone from ₹9.08 to ₹143.75 in a year, with sales up 280% and profits up 306%, my first reaction is caution, not excitement. Anlon Healthcare looks good on the surface: ROCE of 24.83%, debt-equity of only 0.27, and a Piotroski F-Score of 7/9. The latest quarter shows sales of ₹36 Cr and net profit of ₹5 Cr, so the business is genuinely operating. But as Ben Graham taught, price is what you pay, value is what you get. At ₹143.75, the market cap is ₹577 Cr, and the P/B is 28.13 against a book value of just ₹5.11 per share. That means the balance sheet is very thin, and the reported return on equity is inflated by a small equity base. The trailing P/E of 20.48 is not crazy for a growing pharma, but it already assumes this blistering growth will continue. The PEG of 0.07 is seductive, yet PEG is only useful if the growth is durable and of high quality. This kind of growth from a low base is far easier than compounding from scale. There is no dividend, so the only return is price appreciation, and with promoter holding at 52.68%, alignment is decent but the stock has run hard. FairStock calls it 'STEADY' with 55/100, which is odd for a stock that has risen 15-fold. A steady ship doesn't move like that. I want margin of safety, and at this price, I don't see one. I would wait and study the moat, cash conversion, and competitive durability before committing a rupee.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer